▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2142 by analyst upside · 2026-08-12
CVS
CVS Health Corporation
Healthcare · Market Cap $120B · P/E 24.7x
ANALYST PRICE TARGET
+23.9%
implied upside to consensus target
Current Price $93.5
Consensus Target $115.8
Bull Target $148.0
Bear Target $103.0
Analysts Covering 25
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
17
Hold
3
Sell
0
52-Week Low $64.32
52-Week High $110.68
YTD Return +19.4%
FUNDAMENTALS
Market Cap $120B
P/E Ratio (TTM) 24.7x
Forward P/E 11.0x
EPS (TTM) $3.79
PEG Ratio 0.26
Dividend Yield 2.78%
Revenue (TTM) $412.6B
Profit Margin 1.2%
52-WEEK RANGE
52-Week Low $64.32
52-Week High $110.68
Current Price $93.5
Bear Target $103.0
Bull Target $148.0
● Now $93.5 ● Target $115.8
TRADING DATA
Avg Volume 8.3M
YTD Return +19.4%
Analyst Count 25
Consensus Buy
Upside to Target +23.9%
Last Updated 2026-08-12

ANALYST SUMMARY

CVS Health Corporation (CVS) is currently trading at $93.5 with a Wall Street consensus price target of $115.8, implying potential upside of 23.9% over the next 12 months. 25 analysts currently cover CVS, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $148.0, while the most cautious has a target of $103.0.

CVS operates in the Healthcare sector with a market capitalisation of $120B. The stock is up 19.4% year-to-date and is currently trading near the upper end of its 52-week range of $64.32 – $110.68.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MCK +9.9%
McKesson Corporation
$105B · P/E 24.2x · Buy
DHR +9.9%
Danaher Corporation
$146B · P/E 37.0x · Buy
SYK +9.7%
Stryker Corporation
$134B · P/E 36.1x · Buy
VRTX +6.3%
Vertex Pharmaceuticals Incorporated
$134B · P/E 30.8x · Buy
HCA +10.5%
HCA Healthcare, Inc.
$89B · P/E 13.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho - Reiterated
Outperform → Outperform 2026-06-08 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-06-04 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-06-01 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-26 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-05-20 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-14 Building track record
Bernstein - Reiterated
Outperform → Outperform 2026-05-13 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-05-12 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
25/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →